Abstract 174P
Background
Cancer of unknown primary (CUP) is defined as a primary metastatic malignancy, where the primary tumor remains elusive in spite of a comprehensive diagnostic workup. Patients with CUP have a poor prognosis, making the need for the development of novel therapeutic and prognostic tools urgent. The frequency and prognostic value of circulating tumor cells (CTCs), which are considered to be the source of metastasis, has not yet been systematically evaluated in CUP.
Methods
92 patients with a confirmed diagnosis of CUP according to the ESMO guidelines, who presented to our clinic between 07/2021 and 03/2023 provided blood samples for CTC enumeration using CellSearch® methodology. CTC counts were correlated with demographic, clinical and molecular data generated by comprehensive genomic profiling of tumor tissue.
Results
CTCs were detected in 35% of all patients. The highest CTC frequency was observed among patients with unfavorable CUP (18/53, 34%), while patients with single-site/oligometastatic CUP harbored the lowest CTC frequency (4/28, 14%). Disease burden and the number of affected organs had no significant effect on the CTC detection rate (P=0.251 and P=0.805). CDKN2A alterations were slightly more common in CTC-negative patients (P=0.086). High CTC levels (5 CTCs/7.5 ml) predicted for adverse overall survival (OS) compared to negative or low counts (median 74 vs. 19 months; Log-rank P=0.002; HR 3.73; 95% CI 1.54-9.00). Progression-free survival was also affected by CTC status, the effect did not, however, reach statistical significance (median 7.4 vs 3.6 months, Log-rank P=0.1). CTC dynamics over the course of the disease were prognostic for OS, with patients that were either consistently CTC-negative or turned negative during treatment demonstrating the best prognosis.
Conclusions
The number of CTCs is a predictor of survival in patients with CUP. Measurement of CTCs provides a useful prognostic tool in the management of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
German Cancer Research Center.
Disclosure
A. Stenzinger: Financial Interests, Personal, Advisory Board: Aignostics, AstraZeneca, Janssen, Bayer, Seattle Genetics, Pfizer, MSD, Eli Lilly, Illumina, Thermo Fisher, Amgen; Financial Interests, Institutional, Advisory Board: BMS, Takeda, Novartis; Financial Interests, Personal, Invited Speaker: Roche, Incyte; Financial Interests, Institutional, Research Grant: Bayer, Chugai, BMS, Incyte. K. Pantel: Financial Interests, Personal, Advisory Board: Menarini/Silicon Biosystems. All other authors have declared no conflicts of interest.
Resources from the same session
207P - Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Presenter: Maged Khalil
Session: Poster session 01
208P - Identification of BCOR mutation as a novel predictor of immunotherapy efficacy in gastrointestinal tumors
Presenter: Wuping Wang
Session: Poster session 01
209P - Molecular atlas of copy number variation(CNV) in lung cancer with brain metastases
Presenter: Xianfeng Zhang
Session: Poster session 01
210P - Lung tumour vascularity is a risk factor for survival in NSCLC patients undergoing surgery
Presenter: Andrea Riccardo Filippi
Session: Poster session 01
211P - Cost-efficient detection of NTRK1, NTRK2 and NTRK3 gene rearrangements using the test for 5’/3’-end unbalanced expression: The analysis of 8075 patients
Presenter: Evgeny Imyanitov
Session: Poster session 01
212P - Extracellular vesicle miRNA as effective biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade
Presenter: Si Sun
Session: Poster session 01
213P - Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway
Presenter: Hege Russnes
Session: Poster session 01
214P - PESSA: A shiny app for pathway enrichment score-based survival analysis in cancer
Presenter: Ying Shi
Session: Poster session 01
215P - Identifying predictors of overall survival among TMB-low cancer patients treated with immune checkpoint inhibitors
Presenter: Camila Xavier
Session: Poster session 01
216P - PTCH1 mutation as a potential predictor of immune checkpoint inhibitors in gastrointestinal cancer
Presenter: Yang Tang
Session: Poster session 01